Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Axsome Thera
(NQ:
AXSM
)
76.39
+1.21 (+1.61%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Axsome Thera
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Why Axsome Therapeutics Stock Is Sinking Today
June 11, 2024
A short-seller report is causing a sell-off of the biotech stock.
Via
The Motley Fool
15 Analysts Assess Axsome Therapeutics: What You Need To Know
June 05, 2024
Via
Benzinga
Hello Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
May 28, 2024
Via
Benzinga
3 Monster Stocks in the Making You Can Buy Right Now
May 18, 2024
These stocks might not be small for too much longer.
Via
The Motley Fool
The 3 Most Undervalued Biotech Stocks to Buy in May 2024
May 11, 2024
Three most undervalued biotech stocks to buy now will take off in the coming years and bring back continuous, hefty returns.
Via
InvestorPlace
Prediction: These 2 Growth Stocks Could Triple By 2030
May 11, 2024
These companies have a habit of silencing the bears.
Via
The Motley Fool
Peeling Back The Layers: Exploring Axsome Therapeutics Through Analyst Insights
April 29, 2024
Via
Benzinga
Analyst Ratings For Axsome Therapeutics
April 10, 2024
Via
Benzinga
2 Under-the-Radar Growth Stocks to Consider
April 10, 2024
Don't ignore these innovative companies.
Via
The Motley Fool
Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcript
May 06, 2024
AXSM earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
AXSM Stock Earnings: Axsome Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 06, 2024
AXSM stock results show that Axsome Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition
April 30, 2024
Here are our top three choices for biotech stocks with blockbuster drug pipelines that could pay off massively in the future.
Via
InvestorPlace
Billionaires Are Buying These 2 Ultra-High Yield Dividend Stocks Hand Over Fist. Are They Smart Buys for Your Portfolio?
April 16, 2024
Stocks that work for billionaires aren't necessarily appropriate for every investor.
Via
The Motley Fool
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
March 27, 2024
Don’t miss out on these three strong buy biotech stocks that are leaders to add to your portfolio for Q2 this year.
Via
InvestorPlace
What Analysts Are Saying About Axsome Therapeutics Stock
March 19, 2024
Via
Benzinga
What Analysts Are Saying About Axsome Therapeutics Stock
February 27, 2024
Via
Benzinga
Earnings Outlook For Axsome Therapeutics
February 19, 2024
Via
Benzinga
The Latest Analyst Ratings For Axsome Therapeutics
February 06, 2024
Via
Benzinga
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
March 26, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday?
March 25, 2024
Unlock insights from the SYMPHONY Phase 3 trial of AXS-12 (reboxetine) in narcolepsy patients. AXS-12 demonstrated significant reductions in cataplexy attacks, improved daytime wakefulness, and...
Via
Benzinga
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
March 23, 2024
The price could be right for these three biopharma stocks.
Via
The Motley Fool
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
February 26, 2024
Find out which under-the-radar biotech stocks have major catalysts on the horizon, and unlock their explosive growth potential.
Via
InvestorPlace
3 Biotech Stocks to Buy and Hold for the Next 10 Years
February 26, 2024
There's a lot to like about these three drugmakers right now, and that shouldn't stop anytime soon.
Via
The Motley Fool
Axsome Therapeutics (AXSM) Q4 2023 Earnings Call Transcript
February 20, 2024
AXSM earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones
February 20, 2024
Axsome Therapeutics Q4 2023 revenues surge to $71.53 million, Auvelity sales hit $130.1 million for the year. Sunosi sees 67% YoY growth.
Via
Benzinga
Axsome Tumbles On An Unexpected Setback For Its Alzheimer's Drug
February 20, 2024
The company is testing a treatment for patients with agitation due to Alzheimer's disease.
Via
Investor's Business Daily
2 Stocks That Could Double Your Money in 5 Years
February 08, 2024
These market-beating stocks could be just getting started.
Via
The Motley Fool
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
February 06, 2024
UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy.
Via
Benzinga
Cramer Praises Asset Manager's 'Amazing Quarter,' But As For SolarEdge? 'Too Hard To Own'
January 26, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying BlackRock, Inc. (NYSE: BLK).
Via
Benzinga
Earnings Scheduled For February 20, 2024
February 20, 2024
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.